Department of Cardiology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5, Xicheng District, Beijing 100053, China.
Evid Based Complement Alternat Med. 2014;2014:963208. doi: 10.1155/2014/963208. Epub 2014 Feb 16.
To evaluate the clinical curative effects of SPN injection on AP.
Six databases were systematically searched including Cochrane Central, PubMed, EMBASE, CBM, Chinese National Knowledge Infrastructure (CNKI), and VIP to identify randomized controlled trials (RCTs). We assessed the quality of included studies, extracted valid data, and undertook meta-analysis following the steps of systematic review recommended by the Cochrane group.
Ten moderate-to-low quality randomized controlled trials involving 969 patients were included. There was no evidence that SPN alone had better or worse effects than conventional drugs on improving clinical symptoms (RR 1.09, 95% CI 0.85 to 1.39) and ECG (RR 1.17, 95% CI 0.84 to 1.63). However, there was an evidence that SPN combined with western medications was a better treatment option than conventional drugs alone in improving clinical symptoms (RR 1.28, 95% CI 1.19 to 1.33) and ECG (RR 1.27, 95% CI 1.12 to 1.45). No serious adverse effects were reported.
Compared with conventional treatment, SPN may show the potential of optimizing symptomatic outcomes. As a kind of alternative and complementary medicine, SPN may provide another choice for AP patients and further large-scale high-quality trials are needed to confirm this efficacy.
评价参麦注射液治疗急性心肌梗死的临床疗效。
系统检索 Cochrane 图书馆、PubMed、EMBASE、CBM、中国知网(CNKI)、维普数据库,收集参麦注射液治疗急性心肌梗死的随机对照试验,按照 Cochrane 系统评价方法评价纳入研究的质量并提取有效数据,采用 RevMan5.3 软件进行 Meta 分析。
共纳入 10 项中低质量的随机对照试验,合计 969 例患者。结果显示,参麦注射液与常规西药比较,在改善临床症状[RR=1.09,95%CI(0.85,1.39)]和心电图[RR=1.17,95%CI(0.84,1.63)]方面疗效相当;而参麦注射液联合常规西药较常规西药比较,能更有效改善临床症状[RR=1.28,95%CI(1.19,1.33)]和心电图[RR=1.27,95%CI(1.12,1.45)]。未见严重不良反应报道。
与常规西药比较,参麦注射液可能具有优化症状结局的潜力。作为一种替代和补充医学,参麦注射液可能为急性心肌梗死患者提供另一种选择,还需要进一步开展大规模高质量的临床试验来验证其疗效。